News-Medical.Net on MSN1h
New trial shows oral semaglutide reduces cardiovascular events in diabetes patientsBoth the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide ...
MedPage Today on MSN1d
STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery DiseaseCHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
Novo Nordisk (NVO) announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with ...
News-Medical.Net on MSN13h
Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetesSemaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...
Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
BAGSVAERD, Denmark I March 29, 2025 I Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback